Reimbursement framework for medical devices in India
India is an emerging medical device market with huge potential due to its vast population, increasing income, rising healthcare demand, along with increased health insurance coverage. Government-backed schemes such as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) have significantly extended the reach of healthcare services (including medical devices) to wider population. Also, the newly instituted Health Financing and Technology Assessment (HeFTA) unit within the National Health Authority (NHA) will have a greater positive impact on the reimbursement framework in the coming years.
The growth and sustainability of any market, and making innovative technologies accessible to patients depends on a solid reimbursement framework and open price considerations. Considering India’s remarkable growth potential in the medical devices sector, certain aspects of the current reimbursement and pricing framework must be re-evaluated to enable continuing market expansion and access to trailblazing healthcare innovations for patients.
Related Insights
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs
Feb 8, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Whitepaper
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Related Insights
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs
Feb 8, 2022
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Whitepaper
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Blog
Innovative modeling method could speed patient access to critical IO therapies
Jan 4, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023